CD81 and hepatitis C virus (HCV) infection

Viruses

Volumn 6, Issue 2, 2014, Pages 535-572

  Fénéant, Lucie ^a   Levy, Shoshana ^b   Cocquerel, Laurence ^a  

^a UNIV LILLE   (France)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CD81; Entry factors; Hepatitis C virus; Immune response; Tetraspanins; Viral lifecycle

Indexed keywords

ANTIGENS, CD81; HEPACIVIRUS; HOST-PATHOGEN INTERACTIONS; HUMANS; MODELS, BIOLOGICAL; RECEPTORS, VIRUS; VIRUS INTERNALIZATION;

EID: 84893961755     PISSN: 19994915     EISSN: None     Source Type: Journal    
DOI: 10.3390/v6020535     Document Type: Review

References (243)

1. Oren, R.; Takahashi, S.; Doss, C.; Levy, R.; Levy, S. TAPA-1, the target of an antiproliferative antibody, defines a new family of transmembrane proteins. Mol. Cell. Biol. 1990, 10, 4007-4015.
2. Van Spriel, A.B. Tetraspanins in the humoral immune response. Biochem. Soc. Trans. 2011, 39, 512-517.
3. Jones, E.L.; Demaria, M.C.; Wright, M.D. Tetraspanins in cellular immunity. Biochem. Soc. Trans. 2011, 39, 506-511.
4. Levy, S.; Todd, S.C.; Maecker, H.T. CD81 (TAPA-1): A molecule involved in signal transduction and cell adhesion in the immune system. Annu. Rev. Immunol. 1998, 16, 89-109.
5. Levy, S.; Shoham, T. The tetraspanin web modulates immune-signalling complexes. Nat. Rev. Immunol. 2005, 5, 136-148.
6. Monk, P.N.; Partridge, L.J. Tetraspanins: Gateways for infection. Infect. Disord. Drug Targets 2012, 12, 4-17.
7. Lavanchy, D. Evolving epidemiology of hepatitis C virus. Clin. Microbiol. Infect. 2011, 17, 107-115.
8. Lavanchy, D. The global burden of hepatitis C. Liver Int. 2009, 29, 74-81.
9. Lemon, S.M.; Walker, C.; Alter, M.J.; Yi, M. Hepatitis C Virus. In Fields Virology; Knipe, D.M., Ed.; Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2007; Volume 1, pp. 1253-1304.
10. Manns, M.P.; Foster, G.R.; Rockstroh, J.K.; Zeuzem, S.; Zoulim, F.; Houghton, M. The way forward in HCV treatment Finding the right path. Nat. Rev. Drug Discov. 2007, 6, 991-1000.
11. Bacon, B.R.; Gordon, S.C.; Lawitz, E.; Marcellin, P.; Vierling, J.M.; Zeuzem, S.; Poordad, F.; Goodman, Z.D.; Sings, H.L.; Boparai, N.; et al. Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection. N. Engl. J. Med. 2011, 364, 1207-1217.
12. Zeuzem, S.; Andreone, P.; Pol, S.; Lawitz, E.; Diago, M.; Roberts, S.; Focaccia, R.; Younossi, Z.; Foster, G.R.; Horban A.; et al. Telaprevir for Retreatment of HCV Infection. N. Engl. J. Med. 2011, 364, 2417-2428.
13. Barth, H.; Schafer, C.; Adah, M.I.; Zhang, F.; Linhardt, R.J.; Toyoda, H.; Kinoshita-Toyoda, A.; Toida, T.; Van Kuppevelt, T.H.; Depla E; et al. Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J. Biol. Chem. 2003, 278, 41003-41012.
14. Agnello, V.; Abel, G.; Elfahal, M.; Knight, G.B.; Zhang, Q.-X. Hepatitis C virus and other Flaviviridae viruses enter cells via low density lipoprotein receptor. Proc. Natl. Acad. Sci. USA 1999, 96, 12766-12771.
15. Molina, S.; Castet, V.; Pichard-Garcia, L.; Wychowski, C.; Meurs, E.; Pascussi, J.-M.; Sureau, C.; Fabre, J.-M.; Sacunha, A.; Larrey D;et al. Serum-derived hepatitis C virus infection of primary human hepatocytes is tetraspanin CD81 dependent. J. Virol. 2008, 82, 569-574.
16. Pileri, P.; Uematsu, Y.; Campagnoli, S.; Galli, G.; Falugi, F.; Petracca, R.; Weiner, A.J.; Houghton, M.; Rosa, D.; Grandi, G.; et al. Binding of hepatitis C virus to CD81. Science 1998, 282, 938-941.
17. Scarselli, E.; Ansuini, H.; Cerino, R.; Roccasecca, R.M.; Acali, S.; Filocamo, G.; Traboni, C.; Nicosia, A.; Cortese, R.; Vitelli, A. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J. 2002, 21, 5017-5025.
18. Evans, M.J.; von Hahn, T.; Tscherne, D.M.; Syder, A.J.; Panis, M.; Wölk, B.; Hatziioannou, T.; McKeating, J.A.; Bieniasz, P.D.; Rice, C.M. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 2007, 446, 801-805.
19. Liu, S.; Yang, W.; Shen, L.; Turner, J.R.; Coyne, C.B.; Wang, T. Tight junction proteins claudin-1 and occludin control hepatitis C virus entry and are downregulated during infection to prevent superinfection. J. Virol. 2009, 83, 2011-2014.
20. Ploss, A.; Evans, M.J.; Gaysinskaya, V.A.; Panis, M.; You, H.; De Jong, Y.P.; Rice, C.M. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 2009, 457, 882-886.
21. Lupberger, J.; Zeisel, M.-B.; Xiao, F.; Thumann, C.; Fofana, I.; Zona, L.; Davis, C.; Mee, C.J.; Turek, M.; Gorke, S.; et al. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat. Med. 2011, 17, 589-595.
22. Sainz, B.; Barretto, N.; Martin, D.N.; Hiraga, N.; Imamura, M.; Hussain, S.; Marsh, K.A.; Yu, X.; Chayama, K.; Alrefai, W.A.; Uprichard, S.L. Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat. Med. 2012, 18, 281-285.
23. Park, J.H.; Park, S.; Yang, J.-S.; Kwon, O.S.; Kim, S.; Jang, S.K. Discovery of cellular proteins required for the early steps of HCV infection using integrative genomics. PLoS One 2013, 8, e60333.
24. Martin, D.N.; Uprichard, S.L. Identification of transferrin receptor 1 as a hepatitis C virus entry factor. Proc. Natl. Acad. Sci. USA 2013, 110, 10777-10782.
25. Blanchard, E.; Belouzard, S.; Goueslain, L.; Wakita, T.; Dubuisson, J.; Wychowski, C.; Rouille, Y. Hepatitis C virus entry depends on clathrin-mediated endocytosis. J. Virol. 2006, 80, 6964-6972.
26. Meertens, L.; Bertaux, C.; Dragic, T. Hepatitis C virus entry requires a critical postinternalization step and delivery to early endosomes via clathrin-coated vesicles. J. Virol. 2006, 80, 11571-11578.
27. Tscherne, D.M.; Jones, C.T.; Evans, M.J.; Lindenbach, B.D.; McKeating, J.A.; Rice, C.M. Time and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry. J. Virol. 2006, 80, 1734-1741.
28. Hsu, M.; Zhang, J.; Flint, M.; Logvinoff, C.; Cheng-Mayer, C.; Rice, C.M.; McKeating, J.A. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc. Natl. Acad. Sci. USA 2003, 100, 7271-7276.
29. Gastaminza, P.; Cheng, G.; Wieland, S.; Zhong, J.; Liao, W.; Chisari, F.V. Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion. J. Virol. 2008, 82, 2120-2129.
30. Lindenbach, B.D.; Evans, M.J.; Syder, A.J.; Wölk, B.; Tellinghuisen, T.L.; Liu, C.C.; Maruyama, T.; Hynes, R.O.; Burton, D.R.; McKeating, J.A.; Rice, C.M. Complete replication of hepatitis C virus in cell culture. Science 2005, 309, 623-626.
31. Moradpour, D.; Penin, F.; Rice, C.M. Replication of hepatitis C virus. Nat. Rev. Microbiol. 2007, 5, 453-463.
32. Popescu, C.-I.; Dubuisson, J. Role of lipid metabolism in hepatitis C virus assembly and entry. Biol. Cell 2010, 102, 63-74.
33. Lohmann, V.; Körner, F.; Koch, J.; Herian, U.; Theilmann, L.; Bartenschlager, R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999, 285, 110-113.
34. Blight, K.J. Efficient initiation of HCV RNA replication in cell culture. Science 2000, 290, 1972-1974.
35. Flint, M.; Dubuisson, J.; Maidens, C.; Harrop, R.; Guile, G.R.; Borrow, P.; Mckeating, J.A. Functional characterization of intracellular and secreted forms of a truncated hepatitis C virus E2 glycoprotein. J. Virol. 2000, 74, 702-709.
36. Michalak, J.P.; Wychowski, C.; Choukhi, A.; Meunier, J.C.; Ung, S.; Rice, C.M.; Dubuisson, J. Characterization of truncated forms of hepatitis C virus glycoproteins. J. Gen. Virol. 1997, 78, 2299-2306.
37. Deleersnyder, V.; Pillez, A.; Wychowski, C.; Blight, K.; Xu, J.; Hahn, Y.S.; Rice, C.M.; Dubuisson, J. Formation of native hepatitis C virus glycoprotein complexes. J. Virol. 1997, 71, 697-704.
38. Cocquerel, L.; Quinn, E.R.; Flint, M.; Hadlock, K.G.; Foung, S.K. H.; Levy, S. Recognition of native hepatitis C virus E1E2 heterodimers by a human monoclonal antibody. J. Virol. 2003, 77, 1604-1609.
39. Op De Beeck, A.; Voisset, C.; Bartosch, B.; Ciczora, Y.; Cocquerel, L.; Keck, Z.; Foung, S.; Cosset, F.-L.; Dubuisson, J. Characterization of functional hepatitis C virus envelope glycoproteins. J. Virol. 2004, 78, 2994-3002.
40. Vieyres, G.; Thomas, X.; Descamps, V.; Duverlie, G.; Patel, A.H.; Dubuisson, J. Characterization of the envelope glycoproteins associated with infectious hepatitis C virus. J. Virol. 2010, 84, 10159-10168.
41. Owsianka, A.; Clayton, R.F.; Loomis-Price, L.D.; Mckeating, J.A.; Patel, A.H. Functional analysis of hepatitis C virus E2 glycoproteins and virus-like particles reveals structural dissimilarities between different forms of E2. J. Gen. Virol. 2001, 82, 1877-1883.
42. Bartosch, B.; Dubuisson, J.; Cosset, F.-L. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J. Exp. Med. 2003, 197, 633-642.
43. Huang, H.; Sun, F.; Owen, D.M.; Li, W.; Chen, Y.; Gale, M.; Ye, J. Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. Proc. Natl. Acad. Sci. USA 2007, 104, 5848-5853.
44. Bartenschlager, R.; Penin, F.; Lohmann, V.; André, P. Assembly of infectious hepatitis C virus particles. Trends Microbiol. 2010, 19, 95-103.
45. Catanese, M.T.; Uryu, K.; Kopp, M.; Edwards, T.J.; Andrus, L.; Rice, W.J.; Silvestry, M.; Kuhn, R.J.; Rice, C.M. Ultrastructural analysis of hepatitis C virus particles. Proc. Natl. Acad. Sci. USA 2013, 110, 9505-9510.
46. Wakita, T.; Pietschmann, T.; Kato, T.; Date, T.; Miyamoto, M.; Zhao, Z.; Murthy, K.; Habermann, A.; Kräusslich, H.-G.; Mizokami M.; et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 2005, 11, 791-796.
47. Zhong, J.; Gastaminza, P.; Cheng, G.; Kapadia, S.; Kato, T.; Burton, D.R.; Wieland, S.F.; Uprichard, S.L.; Wakita, T.; Chisari, F.V. Robust hepatitis C virus infection in vitro. Proc. Natl. Acad. Sci. USA 2005, 102, 9294-9299.
48. Kitadokoro, K.; Bordo, D.; Galli, G.; Petracca, R.; Falugi, F.; Abrignani, S.; Grandi, G.; Bolognesi, M. CD81 extracellular domain 3D structure: Insight into the tetraspanin superfamily structural motifs. EMBO J. 2001, 20, 12-18.
49. Charrin, S.; Manié, S.; Oualid, M.; Billard, M.; Boucheix, C.; Rubinstein, E. Differential stability of tetraspanin/tetraspanin interactions: Role of palmitoylation. FEBS Lett. 2002, 516, 139-144.
50. Delandre, C.; Penabaz, T.R.; Passarelli, A.L.; Chapes, S.K.; Clem, R.J. Mutation of juxtamembrane cysteines in the tetraspanin CD81 affects palmitoylation and alters interaction with other proteins at the cell surface. Exp. Cell Res. 2009, 315, 1953-1963.
51. Reynolds, G.M.; Harris, H.J.; Jennings, A.; Hu, K.; Grove, J.; Lalor, P.F.; Adams, D.H.; Balfe, P.; Hubscher, S.G.; McKeating, J.A. Hepatitis C virus receptor expression in normal and diseased liver tissue. Hepatology 2007, 47, 418-427.
52. Maecker, H.T.; Levy, S. Normal lymphocyte development but delayed humoral immune response in CD81-null mice. J. Exp. Med. 1997, 185, 1505-1510.
53. Miyazaki, T.; Müller, U.; Campbell, K.S. Normal development but differentially altered proliferative responses of lymphocytes in mice lacking CD81. EMBO J. 1997, 16, 4217-4225.
54. Tsitsikov, E.N.; Gutierrez-Ramos, J.C.; Geha, R.S. Impaired CD19 expression and signaling, enhanced antibody response to type II T independent antigen and reduction of B-1 cells in CD81-deficient mice. Proc. Natl. Acad. Sci. USA 1997, 94, 10844-10849.
55. Rubinstein, E.; Ziyyat, A.; Prenant, M.; Wrobel, E.; Wolf, J.-P.; Levy, S.; Le Naour, F.; Boucheix, C. Reduced fertility of female mice lacking CD81. Dev. Biol. 2006, 290, 351-358.
56. Charrin, S.; Latil, M.; Soave, S.; Polesskaya, A.; Chrétien, F.; Boucheix, C.; Rubinstein, E. Normal muscle regeneration requires tight control of muscle cell fusion by tetraspanins CD9 and CD81. Nat. Comms. 2013, 4, 1674.
57. Silvie, O.; Rubinstein, E.; Franetich, J.-F.; Prenant, M.; Belnoue, E.; Rénia, L.; Hannoun, L.; Eling, W.; Levy, S.; Boucheix, C.; et al. Hepatocyte CD81 is required for Plasmodium falciparum and Plasmodium yoelii sporozoite infectivity. Nat. Med. 2003, 9, 93-96.
58. Yalaoui, S.; Zougbédé, S.; Charrin, S.; Silvie, O.; Arduise, C.; Farhati, K.; Boucheix, C.; Mazier, D.; Rubinstein, E.; Froissard, P. Hepatocyte permissiveness to Plasmodium infection is conveyed by a short and structurally conserved region of the CD81 large extracellular domain. PLoS Pathog. 2008, 4, e1000010.
59. Bartosch, B.; Vitelli, A.; Granier, C.; Goujon, C.; Dubuisson, J.; Pascale, S.; Scarselli, E.; Cortese, R.; Nicosia, A.; Cosset, F.-L. Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J. Biol. Chem. 2003, 278, 41624-41630.
60. Cormier, E.G.; Tsamis, F.; Kajumo, F.; Durso, R.J.; Gardner, J.P.; Dragic, T. CD81 is an entry coreceptor for hepatitis C virus. Proc. Natl. Acad. Sci. USA 2004, 101, 7270-7274.
61. Kapadia, S.B.; Barth, H.; Baumert, T.; McKeating, J.A.; Chisari, F.V. Initiation of hepatitis C virus infection is dependent on cholesterol and cooperativity between CD81 and scavenger receptor B type I. J. Virol. 2007, 81, 374-383.
62. Koutsoudakis, G.; Kaul, A.; Steinmann, E.; Kallis, S.; Lohmann, V.; Pietschmann, T.; Bartenschlager, R. Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. J. Virol. 2006, 80, 5308-5320.
63. Lavillette, D.; Tarr, A.W.; Voisset, C.; Donot, P.; Bartosch, B.; Bain, C.; Patel, A.H.; Dubuisson, J.; Ball, J.K.; Cosset, F.-L. Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus. Hepatology 2005, 41, 265-274.
64. Zhang, J.; Randall, G.; Higginbottom, A.; Monk, P.; Rice, C.M.; McKeating, J.A. CD81 is required for hepatitis C virus glycoprotein-mediated viral infection. J. Virol. 2004, 78, 1448-1455.
65. Meuleman, P.; Hesselgesser, J.; Paulson, M.; Vanwolleghem, T.; Desombere, I.; Reiser, H.; Leroux-Roels, G. Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. Hepatology 2008, 48, 1761-1768.
66. Nakajima, H.; Cocquerel, L.; Kiyokawa, N.; Fujimoto, J.; Levy, S. Kinetics of HCV envelope proteins' interaction with CD81 large extracellular loop. Biochem. Biophys. Res. Commun. 2005, 328, 1091-1100.
67. Mckeating, J.A.; Zhang, L.Q.; Logvinoff, C.; Flint, M.; Zhang, J.; Yu, J.; Butera, D.; Ho, D.D.; Dustin, L.B.; Rice, C.M.; et al. Diverse hepatitis C virus glycoproteins mediate viral infection in a CD81-dependent manner. J. Virol. 2004, 78, 8496-8505.
68. Roccasecca, R.; Ansuini, H.; Vitelli, A.; Meola, A.; Scarselli, E.; Acali, S.; Pezzanera, M.; Ercole, B.B.; McKeating, J.; Yagnik, A.; et al. Binding of the hepatitis C virus E2 glycoprotein to CD81 is strain specific and is modulated by a complex interplay between hypervariable regions 1 and 2. J. Virol. 2003, 77, 1856-1867.
69. Shaw, M.L.; McLauchlan, J.; Mills, P.R.; Patel, A.H.; McCruden, E.A.B. Characterisation of the differences between hepatitis C virus genotype 3 and 1 glycoproteins. J. Med. Virol. 2003, 70, 361-372.
70. Yagnik, A.T.; Lahm, A.; Meola, A.; Roccasecca, R.M.; Ercole, B.B.; Nicosia, A.; Tramontano, A. A model for the hepatitis C virus envelope glycoprotein E2. Proteins 2000, 40, 355-366.
71. Gottwein, J.M.; Scheel, T.K. H.; Jensen, T.B.; Lademann, J.B.; Prentoe, J.C.; Knudsen, M.L.; Hoegh, A.M.; Bukh, J. Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: Role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. Hepatology 2009, 49, 364-377.
72. Akazawa, D.; Date, T.; Morikawa, K.; Murayama, A.; Miyamoto, M.; Kaga, M.; Barth, H.; Baumert, T.-F.; Dubuisson, J.; Wakita, T. CD81 expression is important for the permissiveness of Huh7 cell clones for heterogeneous hepatitis C virus infection. J. Virol. 2007, 81, 5036-5045.
73. Koutsoudakis, G.; Herrmann, E.; Kallis, S.; Bartenschlager, R.; Pietschmann, T. The level of CD81 cell surface expression is a key determinant for productive entry of hepatitis C virus into host cells. J. Virol. 2007, 81, 588-598.
74. Russell, R.S.; Meunier, J.-C.; Takikawa, S.; Faulk, K.; Engle, R.E.; Bukh, J.; Purcell, R.H.; Emerson, S.U. Advantages of a single-cycle production assay to study cell culture-adaptive mutations of hepatitis C virus. Proc. Natl. Acad. Sci. USA 2008, 105, 4370-4375.
75. Rocha-Perugini, V.; Lavie, M.; Delgrange, D.; Canton, J.; Pillez, A.; Potel, J.; Lecoeur, C.; Rubinstein, E.; Dubuisson, J.; Wychowski, C.; et al. The association of CD81 with tetraspanin enriched microdomains is not essential for hepatitis C virus entry. BMC Microbiol. 2009, 9, 111.
76. Padmanabhan, P.; Dixit, N.M. Mathematical model of viral kinetics in vitro estimates the number of E2-CD81 complexes necessary for hepatitis C virus entry. PLoS Comput. Biol. 2011, 7, e1002307.
77. Flint, M.; Maidens, C.; Loomis-Price, L.D.; Shotton, C.; Dubuisson, J.; Monk, P.; Higginbottom, A.; Levy, S.; Mckeating, J.A. Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. J. Virol. 1999, 73, 6235-6244.
78. Flint, M.; Thomas, J.M.; Maidens, C.M.; Shotton, C.; Levy, S.; Barclay, W.S.; Mckeating, J.A. Functional analysis of cell surface-expressed hepatitis C virus E2 glycoprotein. J. Virol. 1999, 73, 6782-6790.
79. Masciopinto, F.; Campagnoli, S.; Abrignani, S.; Uematsu, Y.; Pileri, P. The small extracellular loop of CD81 is necessary for optimal surface expression of the large loop, a putative HCV receptor. Virus Res. 2001, 80, 1-10.
80. Montpellier, C.; Tews, B.A.; Poitrimole, J.; Rocha-Perugini, V.; D'Arienzo, V.; Potel, J.; Zhang, X.A.; Rubinstein, E.; Dubuisson, J.; Cocquerel, L. Interacting regions of CD81 and two of its partners, EWI-2 and EWI-2wint, and their effect on hepatitis C virus infection. J. Biol. Chem. 2011, 286, 13954-13965.
81. Higginbottom, A.; Quinn, E.R.; Kuo, C.C.; Flint, M.; Wilson, L.H.; Bianchi, E.; Nicosia, A.; Monk, P.N.; Mckeating, J.A.; Levy, S. Identification of amino acid residues in CD81 critical for interaction with hepatitis C virus envelope glycoprotein E2. J. Virol. 2000, 74, 3642-3649.
82. Petracca, R.; Falugi, F.; Galli, G.; Norais, N.; Rosa, D.; Campagnoli, S.; Burgio, V.; Di Stasio, E.; Giardina, B.; Houghton, M.; et al. Structure-function analysis of hepatitis C virus envelope-CD81 binding. J. Virol. 2000, 74, 4824-4830.
83. Drummer, H.E.; Wilson, K.A.; Poumbourios, P. Identification of the hepatitis C virus E2 glycoprotein binding site on the large extracellular loop of CD81. J. Virol. 2002, 76, 11143-11147.
84. Kong, L.; Giang, E.; Nieusma, T.; Kadam, R.U.; Cogburn, K.E.; Hua, Y.; Dai, X.; Stanfield, R.L.; Burton, D.R.; Ward, A.B.; et al. Hepatitis C Virus E2 envelope glycoprotein core structure. Science 2013, 342, 1090-1094.
85. Rajesh, S.; Sridhar, P.; Tews, B.A.; Feneant, L.; Cocquerel, L.; Ward, D.G.; Berditchevski, F.; Overduin, M. Structural basis of ligand interactions of the large extracellular domain of tetraspanin CD81. J. Virol. 2012, 86, 9606-9616.
86. Drummer, H.E.; Wilson, K.A.; Poumbourios, P. Determinants of CD81 dimerization and interaction with hepatitis C virus glycoprotein E2. Biochem. Biophys. Res. Commun. 2005, 328, 251-257.
87. Flint, M.; Hahn, von, T.; Zhang, J.; Farquhar, M.; Jones, C.T.; Balfe, P.; Rice, C.M.; McKeating, J.A. Diverse CD81 proteins support hepatitis C virus infection. J. Virol. 2006, 80, 11331-11342.
88. Bitzegeio, J.; Bankwitz, D.; Hueging, K.; Haid, S.; Brohm, C.; Zeisel, M.-B.; Herrmann, E.; Iken, M.; Ott, M.; Baumert, T.-F; et al. Adaptation of hepatitis C virus to mouse CD81 permits infection of mouse cells in the absence of human entry factors. PLoS Pathog. 2010, 6, e1000978.
89. Krieger, S.E.; Zeisel, M.-B.; Davis, C.; Thumann, C.; Harris, H.J.; Schnober, E.K.; Mee, C.; Soulier, E.; Royer, C.; Lambotin, M.; et al. Inhibition of hepatitis C virus infection by anticlaudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations. Hepatology 2010, 51, 1144-1157.
90. Deest, M.; Westhaus, S.; Steinmann, E.; Manns, M.P.; von Hahn, T.; Ciesek, S. Impact of single nucleotide polymorphisms in the essential HCV entry factor CD81 on HCV infectivity and neutralization. Antivir. Res. 2014, 101, 37-44.
91. Houldsworth, A.; Metzner, M.M.; Demaine, A.; Hodgkinson, A.; Kaminski, E.; Cramp, M. CD81 sequence and susceptibility to hepatitis C infection. J. Med. Virol. 2014, 86, 162-168.
92. Wang, Y.; Keck, Z.-Y.; Foung, S.K. H. Neutralizing antibody response to hepatitis C virus. Viruses 2011, 3, 2127-2145.
93. Allander, T.; Forns, X.; Emerson, S.U.; Purcell, R.H.; Bukh, J. Hepatitis C virus envelope protein E2 binds to CD81 of tamarins. Virology 2000, 277, 358-367.
94. Keck, Z.-Y.; Op De Beeck, A.; Hadlock, K.G.; Xia, J.; Li, T.-K.; Dubuisson, J.; Foung, S.K.H. Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions. J. Virol. 2004, 78, 9224-9232.
95. Hadlock, K.G.; Lanford, R.E.; Perkins, S.; Rowe, J.; Yang, Q.; Levy, S.; Pileri, P.; Abrignani, S.; Foung, S.K. Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes. J. Virol. 2000, 74, 10407-10416.
96. Keck, Z.-Y.; Li, T.-K.; Xia, J.; Gal-Tanamy, M.; Olson, O.; Li, S.H.; Patel, A.H.; Ball, J.K.; Lemon, S.M.; Foung, S.K.H. Definition of a conserved immunodominant domain on hepatitis C virus E2 glycoprotein by neutralizing human monoclonal antibodies. J. Virol. 2008, 82, 6061-6066.
97. Keck, Z.Y.; Saha, A.; Xia, J.; Wang, Y.; Lau, P.; Krey, T.; Rey, F.A.; Foung, K.H. Mapping a region of hepatitis C virus E2 that is responsible for escape from neutralizing antibodies and a core CD81-binding region that does not tolerate neutralization escape mutations. J. Virol. 2011, 85, 10451.
98. Bankwitz, D.; Steinmann, E.; Bitzegeio, J.; Ciesek, S.; Friesland, M.; Herrmann, E.; Zeisel, M.-B.; Baumert, T.-F.; Keck, Z.-Y.; Foung, S.K.H; et al. Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes. J. Virol. 2010, 84, 5751-5763.
99. Owsianka, A.M.; Timms, J.M.; Tarr, A.W.; Brown, R.J.P.; Hickling, T.P.; Szwejk, A.; Bienkowska-Szewczyk, K.; Thomson, B.J.; Patel, A.H.; Ball, J.K. Identification of conserved residues in the E2 envelope glycoprotein of the hepatitis C virus that are critical for CD81 binding. J. Virol. 2006, 80, 8695-8704.
100. Tarr, A.W.; Owsianka, A.M.; Timms, J.M.; McClure, C.P.; Brown, R.J.P.; Hickling, T.P.; Pietschmann, T.; Bartenschlager, R.; Patel, A.H.; Ball, J.K. Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33. Hepatology 2006, 43, 592-601.
101. Kong, L.; Giang, E.; Robbins, J.B.; Stanfield, R.L.; Burton, D.R.; Wilson, I.A.; Law, M. Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1. Proc. Natl. Acad. Sci. USA 2012, 109, 9499-9504.
102. Kong, L.; Giang, E.; Nieusma, T.; Robbins, J.B.; Deller, M.C.; Stanfield, R.L.; Wilson, I.A.; Law, M. Structure of hepatitis C virus envelope glycoprotein E2 antigenic site 412 to 423 in complex with antibody AP33. J. Virol. 2012, 86, 13085-13088.
103. Potter, J.A.; Owsianka, A.M.; Jeffery, N.; Matthews, D.J.; Keck, Z.Y.; Lau, P.; Foung, S.K.H.; Taylor, G.L.; Patel, A.H. Toward a hepatitis C virus vaccine: The structural basis of hepatitis C virus neutralization by AP33, a broadly neutralizing antibody. J. Virol. 2012, 86, 12923-12932.
104. Krey, T.; Meola, A.; Keck, Z.-Y.; Damier-Piolle, L.; Foung, S.K.H.; Rey, F.A. Structural basis of HCV neutralization by human monoclonal antibodies resistant to viral neutralization escape. PLoS Pathog. 2013, 9, e1003364.
105. Forns, X.; Allander, T.; Rohwer-Nutter, P.; Bukh, J. Characterization of modified hepatitis C virus E2 proteins expressed on the cell surface. Virology 2000, 274, 75-85.
106. Patel, A.H.; Wood, J.; Penin, F.; Dubuisson, J.; Mckeating, J.A. Construction and characterization of chimeric hepatitis C virus E2 glycoproteins: Analysis of regions critical for glycoprotein aggregation and CD81 binding. J. Gen. Virol. 2000, 81, 2873-2883.
107. Callens, N.; Ciczora, Y.; Bartosch, B.; Vu-Dac, N.; Cosset, F.-L.; Pawlotsky, J.-M.; Penin, F.; Dubuisson, J. Basic residues in hypervariable region 1 of hepatitis C virus envelope glycoprotein e2 contribute to virus entry. J. Virol. 2005, 79, 15331-15341.
108. Drummer, H.E.; Boo, I.; Maerz, A.L.; Poumbourios, P. A conserved Gly436-Trp-Leu-Ala-Gly-Leu-Phe-Tyr motif in hepatitis C virus glycoprotein E2 is a determinant of CD81 binding and viral entry. J. Virol. 2006, 80, 7844-7853.
109. Owsianka, A.M.; Tarr, A.W.; Keck, Z.-Y.; Li, T.-K.; Witteveldt, J.; Adair, R.; Foung, S.K.H.; Ball, J.K.; Patel, A.H. Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein. J. Gen. Virol. 2008, 89, 653-659.
110. Rothwangl, K.B.; Manicassamy, B.; Uprichard, S.L.; Rong, L. Dissecting the role of putative CD81 binding regions of E2 in mediating HCV entry: Putative CD81 binding region 1 is not involved in CD81 binding. Virol. J. 2008, 5, 46.
111. Grove, J.; Nielsen, S.; Zhong, J.; Bassendine, M.F.; Drummer, H.E.; Balfe, P.; McKeating, J.A. Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies. J. Virol. 2008, 82, 12020-12029.
112. Dhillon, S.; Witteveldt, J.; Gatherer, D.; Owsianka, A.M.; Zeisel, M.-B.; Zahid, M.N.; Rychłowska, M.; Foung, S.K.H.; Baumert, T.-F.; Angus, A.G.N.; et al. Mutations within a conserved region of the hepatitis C virus E2 glycoprotein that influence virus-receptor interactions and sensitivity to neutralizing antibodies. J. Virol. 2010, 84, 5494-5507.
113. Krey, T.; d'Alayer, J.; Kikuti, C.M.; Saulnier, A.; Damier-Piolle, L.; Petitpas, I.; Johansson, D.X.; Tawar, R.G.; Baron, B.; Robert, B.; et al. The Disulfide Bonds in Glycoprotein E2 of Hepatitis C Virus Reveal the Tertiary Organization of the Molecule. PLoS Pathog. 2010, 6, e1000762.
114. McCaffrey, K.; Gouklani, H.; Boo, I.; Poumbourios, P.; Drummer, H.E. The variable regions of hepatitis C virus glycoprotein E2 have an essential structural role in glycoprotein assembly and virion infectivity. J. Gen. Virol. 2011, 92, 112-121.
115. Boo, I.; Tewierek, K.; Douam, F.; Lavillette, D.; Poumbourios, P.; Drummer, H. Distinct roles in folding, CD81 receptor binding and viral entry for conserved histidines of HCV glycoprotein E1 and E2. Biochem. J. 2012, 443, 85-94.
116. Falkowska, E.; Kajumo, F.; Garcia, E.; Reinus, J.; Dragic, T. Hepatitis C virus envelope glycoprotein E2 glycans modulate entry, CD81 binding, and neutralization. J. Virol. 2007, 81, 8072-8079.
117. Goffard, A.; Callens, N.; Bartosch, B.; Wychowski, C.; Cosset, F.-L.; Montpellier, C.; Dubuisson, J. Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins. J. Virol. 2005, 79, 8400-8409.
118. Helle, F.; Vieyres, G.; Elkrief, L.; Popescu, C.-I.; Wychowski, C.; Descamps, V.; Castelain, S.; Roingeard, P.; Duverlie, G.; Dubuisson, J. Role of N-linked glycans in the functions of hepatitis C virus envelope proteins incorporated into infectious virions. J. Virol. 2010, 84, 11905-11915.
119. Helle, F.; Goffard, A.; Morel, V.; Duverlie, G.; McKeating, J.; Keck, Z.-Y.; Foung, S.; Penin, F.; Dubuisson, J.; Voisset, C. The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein. J. Virol. 2007, 81, 8101-8111.
120. Lavie, M.L.; Dubuisson, J. HCV glycoprotein assembly of a functional E1-E2 heterodimer. In Hepatitis C Viruses: Genomes and Molecular Biology; Tan, S.L., Ed.; Horizon Bioscience: Norfolk, UK, 2006; pp. 1-30.
121. Wahid, A.; Helle, F.; Descamps, V.; Duverlie, G.; Penin, F.; Dubuisson, J. Disulfide bonds in hepatitis C virus glycoprotein E1 control the assembly and entry functions of E2 glycoprotein. J. Virol. 2013, 87, 1605-1617.
122. Fraser, J.; Boo, I.; Poumbourios, P.; Drummer, H.E. Hepatitis C Virus (HCV) envelope glycoproteins E1 and E2 contain reduced cysteine residues essential for virus entry. J. Biol. Chem. 2011, 286, 31984.
123. Masciopinto, F.; Freer, G.; Burgio, V.L.; Levy, S.; Galli-Stampino, L.; Bendinelli, M.; Houghton, M.; Abrignani, S.; Uematsu, Y. Expression of human CD81 in transgenic mice does not confer susceptibility to hepatitis C virus infection. Virology 2002, 304, 187-196.
124. Meola, A.; Sbardellati, A.; Bruni Ercole, B.; Cerretani, M.; Pezzanera, M.; Ceccacci, A.; Vitelli, A.; Levy, S.; Nicosia, A.; Traboni, C.; et al. Binding of hepatitis C virus E2 glycoprotein to CD81 does not correlate with species permissiveness to infection. J. Virol. 2000, 74, 5933-5938.
125. Zhao, X.; Tang, Z.-Y.; Klumpp, B.; Wolff-Vorbeck, G.; Barth, H.; Levy, S.; von Weizsacker, F.; Blum, H.E.; Baumert, T.-F. Primary hepatocytes of Tupaia belangeri as a potential model for hepatitis C virus infection. J. Clin. Invest. 2002, 109, 221-232.
126. Xie, Z.C.; Riezu-Boj, J.I.; Lasarte, J.J.; Guillen, J.; Su, J.H.; Civeira, M.P.; Prieto, J. Transmission of hepatitis C virus infection to tree shrews. Virology 1998, 244, 513-520.
127. Xu, X.; Chen, H.; Cao, X.; Ben, K. Efficient infection of tree shrew (Tupaia belangeri) with hepatitis C virus grown in cell culture or from patient plasma. J. Gen. Virol. 2007, 88, 2504-2512.
128. Tian, Z.-F.; Shen, H.; Fu, X.-H.; Chen, Y.-C.; Blum, H.E.; Baumert, T.-F.; Zhao, X.-P. Interaction of hepatitis C virus envelope glycoprotein E2 with the large extracellular loop of tupaia CD81. World J. Gastroenterol. 2009, 15, 240-244.
129. Tong, Y.; Zhu, Y.; Xia, X.; Liu, Y.; Feng, Y.; Hua, X.; Chen, Z.; Ding, H.; Gao, L.; Wang, Y.; et al. Tupaia CD81, SR-BI, claudin-1, and occludin support hepatitis C virus infection. J. Virol. 2011, 85, 2793-2802.
130. Dorner, M.; Horwitz, J.A.; Robbins, J.B.; Barry, W.T.; Feng, Q.; Mu, K.; Jones, C.T.; Schoggins, J.W.; Catanese, M.T.; Burton, D.R.; et al. A genetically humanized mouse model for hepatitis C virus infection. Nature 2011, 474, 208-211.
131. Dorner, M.; Horwitz, J.A.; Donovan, B.M.; Labitt, R.N.; Budell, W.C.; Friling, T.; Vogt, A.; Catanese, M.T.; Satoh, T.; Kawai, T.; et al. Completion of the entire hepatitis c virus life cycle in genetically humanized mice. Nature 2013, 501, 237-241.
132. Zona, L.; Lupberger, J.; Sidahmed-Adrar, N.; Thumann, C.; Harris, H.J.; Barnes, A.; Florentin, J.; Tawar, R.G.; Xiao, F.; Turek, M.; et al. HRas signal transduction promotes hepatitis C virus cell entry by triggering assembly of the host tetraspanin receptor complex. Cell Host Microbe 2013, 13, 302-313.
133. Catanese, M.T.; Graziani, R.; von Hahn, T.; Moreau, M.; Huby, T.; Paonessa, G.; Santini, C.; Luzzago, A.; Rice, C.M.; Cortese, R.; et al. High-avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein. J. Virol. 2007, 81, 8063-8071.
134. Catanese, M.T.; Ansuini, H.; Graziani, R.; Huby, T.; Moreau, M.; Ball, J.K.; Paonessa, G.; Rice, C.M.; Cortese, R.; Vitelli, A.; et al. Role of scavenger receptor class B type I in hepatitis C virus entry: Kinetics and molecular determinants. J. Virol. 2010, 84, 34-43.
135. Dreux, M.; Dao Thi, V.L.; Fresquet, J.; Guérin, M.; Julia, Z.; Verney, G.; Durantel, D.; Zoulim, F.; Lavillette, D.; Cosset, F.-L.; et al. Receptor complementation and mutagenesis reveal SR-BI as an essential HCV entry factor and functionally imply its intra and extra-cellular domains. PLoS Pathog. 2009, 5, e1000310.
136. Grove, J.; Huby, T.; Stamataki, Z.; Vanwolleghem, T.; Meuleman, P.; Farquhar, M.; Schwarz, A.; Moreau, M.; Owen, J.S.; Leroux-Roels, G.; et al. Scavenger receptor BI and BII expression levels modulate hepatitis C virus infectivity. J. Virol. 2007, 81, 3162-3169.
137. Zeisel, M.-B.; Koutsoudakis, G.; Schnober, E.K.; Haberstroh, A.; Blum, H.E.; Cosset, F.-L.; Wakita, T.; Jaeck, D.; Doffoel, M.; Royer, C.; et al. Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81. Hepatology 2007, 46, 1722-1731.
138. Schwarz, A.K.; Grove, J.; Hu, K.; Mee, C.J.; Balfe, P.; McKeating, J.A. Hepatoma cell density promotes claudin-1 and scavenger receptor BI expression and hepatitis C virus internalization. J. Virol. 2009, 83, 12407-12414.
139. Zahid, M.N.; Turek, M.; Xiao, F.; Dao Thi, V.L.; Guérin, M.; Fofana, I.; Bachellier, P.; Thompson, J.; Delang, L.; Neyts, J.; et al. The postbinding activity of scavenger receptor class B type I mediates initiation of hepatitis C virus infection and viral dissemination. Hepatology 2012, 57, 492-504.
140. Neculai, D.; Schwake, M.; Ravichandran, M.; Zunke, F.; Collins, R.F.; Peters, J.; Neculai, M.; Plumb, J.; Loppnau, P.; Pizarro, J.C.; et al. Structure of LIMP-2 provides functional insightswith implications for SR-BI and CD36. Nature 2013, 504, 172-176.
141. Dao Thi, V.L.; Dreux, M.; Cosset, F.-L. Scavenger receptor class B type I and the hypervariable region-1 of hepatitis C virus in cell entry and neutralisation. Expert Rev. Mol. Med. 2011, 13, e13
142. Meertens, L.; Bertaux, C.; Cukierman, L.; Cormier, E.; Lavillette, D.; Cosset, F.-L.; Dragic, T. The tight junction proteins claudin-1,-6, and-9 are entry cofactors for hepatitis C virus. J. Virol. 2008, 82, 3555-3560.
143. Zheng, A.; Yuan, F.; Li, Y.; Zhu, F.; Hou, P.; Li, J.; Song, X.; Ding, M.; Deng, H. Claudin-6 and claudin-9 function as additional coreceptors for hepatitis C virus. J. Virol. 2007, 81, 12465-12471.
144. Douam, F.; Thi, V.L.D.; Maurin, G.; Fresquet, J.; Mompelat, D.; Zeisel, M.-B.; Baumert, T.-F.; Cosset, F.-L.; Lavillette, D. A critical interaction between E1 and E2 glycoproteins determines binding and fusion properties of hepatitis C virus during cell entry. Hepatology 2013, doi:10.1002/hep.26733.
145. Fofana, I.; Krieger, S.E.; Grunert, F.; Glauben, S.; Xiao, F.; Fafi-Kremer, S.; Soulier, E.; Royer, C.; Thumann, C.; Mee, C.J.; et al. Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes. Gastroenterology 2010, 139, 953-64, 964.e1-4.
146. Benedicto, I.; Molina-Jiménez, F.; Bartosch, B.; Cosset, F.-L.; Lavillette, D.; Prieto, J.; Moreno Otero, R.; Valenzuela-Fernández, A.; Aldabe, R.; López-Cabrera, M.; et al. The tight junction associated protein occludin is required for a postbinding step in hepatitis C virus entry and infection. J. Virol. 2009, 83, 8012-8020.
147. Yang, W.; Qiu, C.; Biswas, N.; Jin, J.; Watkins, S.C.; Montelaro, R.C.; Coyne, C.B.; Wang, T. Correlation of the tight junction-like distribution of Claudin-1 to the cellular tropism of hepatitis C virus. J. Biol. Chem. 2008, 283, 8643-8653.
148. Harris, H.J.; Farquhar, M.J.; Mee, C.J.; Davis, C.; Reynolds, G.M.; Jennings, A.; Hu, K.; Yuan, F.; Deng, H.; Hubscher, S.G.; et al. CD81 and claudin 1 coreceptor association: Role in hepatitis C virus entry. J. Virol. 2008, 82, 5007-5020.
149. Harris, H.J.; Davis, C.; Mullins, J.G.L.; Hu, K.; Goodall, M.; Farquhar, M.J.; Mee, C.J.; McCaffrey, K.; Young, S.; Drummer, H.; et al. Claudin association with CD81 defines hepatitis C virus entry. J. Biol. Chem. 2010, 285, 21092-21102.
150. Mee, C.J.; Harris, H.J.; Farquhar, M.J.; Wilson, G.; Reynolds, G.; Davis, C.; van Ijzendoorn, S.C.D.; Balfe, P.; McKeating, J.A. Polarization restricts hepatitis C virus entry into HepG2 hepatoma cells. J. Virol. 2009, 83, 6211-6221.
151. Davis, C.; Harris, H.J.; Hu, K.; Drummer, H.E.; McKeating, J.A.; Mullins, J.G.L.; Balfe, P. In silico directed mutagenesis identifies the CD81/claudin-1 hepatitis C virus receptor interface. Cell. Microbiol. 2012, 14, 1892-1903.
152. Bonifacino, J.S.; Dell'Angelica, E.C. Molecular bases for the recognition of tyrosine-based sorting signals. J. Cell Biol. 1999, 145, 923-926.
153. Haucke, V.; Krauss, M. Tyrosine-based endocytic motifs stimulate oligomerization of AP-2 adaptor complexes. Eur. J. Cell Biol. 2002, 81, 647-653.
154. Utech, M.; Mennigen, R.; Bruewer, M. Endocytosis and recycling of tight junction proteins in inflammation. J. Biomed. Biotechnol. 2010, 2010, 484987.
155. Yu, D.; Turner, J.R. Stimulus-induced reorganization of tight junction structure: The role of membrane traffic. Biochim. Biophys. Acta 2008, 1778, 709-716.
156. Farquhar, M.J.; Hu, K.; Harris, H.J.; Davis, C.; Brimacombe, C.L.; Fletcher, S.J.; Baumert, T.F.; Rappoport, J.Z.; Balfe, P.; Mckeating, J.A. Hepatitis C virus induces CD81 and Claudin-1 endocytosis. J. Virol. 2012, 86, 4305-4316.
157. Diao, J.; Pantua, H.; Ngu, H.; Komuves, L.; Diehl, L.; Schaefer, G.; Kapadia, S.B. Hepatitis C virus induces epidermal growth factor receptor activation via CD81 binding for viral internalization and entry. J. Virol. 2012, 86, 10935-10949.
158. Coyne, C.B.; Bergelson, J.M. Virus-induced Abl and Fyn kinase signals permit coxsackievirus entry through epithelial tight junctions. Cell 2006, 124, 119-131.
159. Brazzoli, M.; Bianchi, A.; Filippini, S.; Weiner, A.; Zhu, Q.; Pizza, M.; Crotta, S. CD81 is a central regulator of cellular events required for hepatitis C virus infection of human hepatocytes. J. Virol. 2008, 82, 8316-8329.
160. Reynolds, G.M.; Harris, H.J.; Jennings, A.; Hu, K.; Grove, J.; Lalor, P.F.; Adams, D.H.; Balfe, P.; Hübscher, S.G.; McKeating, J.A. Hepatitis C virus receptor expression in normal and diseased liver tissue. Hepatology 2008, 47, 418-427.
161. Heiskala, M.; Peterson, P.A.; Yang, Y. The roles of claudin superfamily proteins in paracellular transport. Traffic 2001, 2, 93-98.
162. Mee, C.J.; Grove, J.; Harris, H.J.; Hu, K.; Balfe, P.; McKeating, J.A. Effect of cell polarization on hepatitis C virus entry. J. Virol. 2008, 82, 461-470.
163. Coller, K.E.; Berger, K.L.; Heaton, N.S.; Cooper, J.D.; Yoon, R.; Randall, G. RNA interference and single particle tracking analysis of hepatitis C virus endocytosis. PLoS Pathog. 2009, 5, e1000702.
164. Sourisseau, M.; Michta, M.L.; Zony, C.; Israelow, B.; Hopcraft, S.E.; Narbus, C.M.; Parra Martín, A.; Evans, M.J. Temporal analysis of Hepatitis C Virus cell entry with occludin directed blocking antibodies. PLoS Pathog. 2013, 9, e1003244.
165. Liu, S.; Kuo, W.; Yang, W.; Liu, W.; Gibson, G.A.; Dorko, K.; Watkins, S.C.; Strom, S.C.; Wang, T. The second extracellular loop dictates Occludin-mediated HCV entry. Virology 2010, 407, 160-170.
166. Sharma, N.R.; Mateu, G.; Dreux, M.; Grakoui, A.; Cosset, F.-L.; Melikyan, G.B. Hepatitis C virus is primed by CD81 protein for low pH-dependent fusion. J. Biol. Chem. 2011, 286, 30361-30376
167. Chang, M.; Williams, O.; Mittler, J.; Quintanilla, A.; Carithers, R.L.; Perkins, J.; Corey, L.; Gretch, D.R. Dynamics of hepatitis C virus replication in human liver. Am. J. Pathol. 2003, 163, 433-444.
168. Wieland, S.; Makowska, Z.; Campana, B.; Calabrese, D.; Dill, M.T.; Chung, J.; Chisari, F.V.; Heim, M.H. Simultaneous detection of hepatitis C virus and interferon stimulated gene expression in infected human liver. Hepatology 2013, doi:10.1002/hep.26770.
169. Brimacombe, C.L.; Grove, J.; Meredith, L.W.; Hu, K.; Syder, A.J.; Flores, M.V.; Timpe, J.M.; Krieger, S.E.; Baumert, T.-F.; Tellinghuisen, T.L.; et al. Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission. J. Virol. 2011, 85, 596-605.
170. Ciesek, S.; Westhaus, S.; Wicht, M.; Wappler, I.; Henschen, S.; Sarrazin, C.; Hamdi, N.; Abdelaziz, A.I.; Strassburg, C.P.; Wedemeyer, H.; et al. Impact of intra and interspecies variation of occludin on its function as coreceptor for authentic hepatitis C virus particles. J. Virol. 2011, 85, 7613-7621.
171. Meredith, L.W.; Harris, H.J.; Wilson, G.K.; Fletcher, N.F.; Balfe, P.; McKeating, J.A. Early infection events highlight the limited transmissibility of hepatitis C virus in vitro. J. Hepatol. 2013, 58, 1074-1080.
172. Catanese, M.T.; Loureiro, J.; Jones, C.T.; Dorner, M.; von Hahn, T.; Rice, C.M. Different requirements for scavenger receptor class B type I in hepatitis C virus cell-free versus cell-to-cell transmission. J. Virol. 2013, 87, 8282-8293.
173. Valli, M.B.; Crema, A.; Lanzilli, G.; Serafino, A.; Bertolini, L.; Ravagnan, G.; Ponzetto, A.; Menzo, S.; Clementi, M.; Carloni, G. Molecular and cellular determinants of cell-to-cell transmission of HCV in vitro. J. Med. Virol. 2007, 79, 1491-1499.
174. Timpe, J.M.; Stamataki, Z.; Jennings, A.; Hu, K.; Farquhar, M.J.; Harris, H.J.; Schwarz, A.; Desombere, I.; Roels, G.L.; Balfe, P.; et al. Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. Hepatology 2008, 47, 17-24.
175. Witteveldt, J.; Evans, M.J.; Bitzegeio, J.; Koutsoudakis, G.; Owsianka, A.M.; Angus, A.G.N.; Keck, Z.-Y.; Foung, S.K.H.; Pietschmann, T.; Rice, C.M.; et al. CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells. J. Gen. Virol. 2009, 90, 48-58.
176. Jones, C.T.; Catanese, M.T.; Law, L.M.J.; Khetani, S.R.; Syder, A.J.; Ploss, A.; Oh, T.S.; Schoggins, J.W.; MacDonald, M.R.; Bhatia, S.N.; et al. Real-time imaging of hepatitis C virus infection using a fluorescent cell-based reporter system. Nat. Biotechnol. 2010, 28, 167-171.
177. Potel, J.; Rassam, P.; Montpellier, C.; Kaestner, L.; Werkmeister, E.; Tews, B.A.; Couturier, C.; Popescu, C.-I.; Baumert, T.-F.; Rubinstein, E.; et al. EWI-2wint promotes CD81 clustering that abrogates hepatitis C virus entry. Cell. Microbiol. 2013, 15, 1234-1252.
178. Sattentau, Q.J. Cell-to-cell spread of retroviruses. Viruses 2010, 2, 1306-1321.
179. Perez-Hernandez, D.; Gutierrez-Vazquez, C.; Jorge, I.; Lopez-Martin, S.; Ursa, A.; Sánchez Madrid, F.; Vazquez, J.; Yáñez-Mó, M. The intracellular interactome of tetraspanin-enriched microdomains reveals their function as sorting machineries toward exosomes. J. Biol. Chem. 2013, 288, 11649-11661.
180. Ramakrishnaiah, V.; Thumann, C.; Fofana, I.; Habersetzer, F.; Pan, Q.; de Ruiter, P.E.; Willemsen, R.; Demmers, J.A.A.; Stalin Raj, V.; Jenster, G.; et al. Exosome-mediated transmission of hepatitis C virus between human hepatoma Huh7.5 cells. Proc. Natl. Acad. Sci. USA 2013, 110, 13109-13113.
181. Charrin, S.; Le Naour, F.; Silvie, O.; Milhiet, P.-E.; Boucheix, C.; Rubinstein, E. Lateral organization of membrane proteins: Tetraspanins spin their web. Biochem. J. 2009, 420, 133-154.
182. Bradbury, L.E.; Kansas, G.S.; Levy, S.; Evans, R.L.; Tedder, T.F. The CD19/CD21 signal transducing complex of human B lymphocytes includes the target of antiproliferative antibody-1 and Leu-13 molecules. J. Immunol. 1992, 149, 2841-2850.
183. Imai, T.; Yoshie, O. C33 antigen and M38 antigen recognized by monoclonal antibodies inhibitory to syncytium formation by human T cell leukemia virus type 1 are both members of the transmembrane 4 superfamily and associate with each other and with CD4 or CD8 in T cells. J. Immunol. 1993, 151, 6470-6481.
184. Serru, V.; Le Naour, F.; Billard, M.; Azorsa, D.O.; Lanza, F.; Boucheix, C.; Rubinstein, E. Selective tetraspan-integrin complexes (CD81/alpha4beta1, CD151/alpha3beta1, CD151/alpha6beta1) under conditions disrupting tetraspan interactions. Biochem. J. 1999, 340, 103-111.
185. Rubinstein, E.; Le Naour, F.; Lagaudrière-Gesbert, C.; Billard, M.; Conjeaud, H.; Boucheix, C. CD9, CD63, CD81, and CD82 are components of a surface tetraspan network connected to HLA DR and VLA integrins. Eur. J. Immunol. 1996, 26, 2657-2665.
186. Charrin, S.; Le Naour, F.; Labas, V.; Billard, M.; Le Caer, J.-P.; Emile, J.-F.; Petit, M.-A.; Boucheix, C.; Rubinstein, E. EWI-2 is a new component of the tetraspanin web in hepatocytes and lymphoid cells. Biochem. J. 2003, 373, 409-421.
187. Charrin, S.; Le Naour, F.; Oualid, M.; Billard, M.; Faure, G.; Hanash, S.M.; Boucheix, C.; Rubinstein, E. The major CD9 and CD81 molecular partner. Identification and characterization of the complexes. J. Biol. Chem. 2001, 276, 14329-14337.
188. Clark, K.L.; Zeng, Z.; Langford, A.L.; Bowen, S.M.; Todd, S.C. PGRL is a major CD81 associated protein on lymphocytes and distinguishes a new family of cell surface proteins. J. Immunol. 2001, 167, 5115-5121.
189. Rocha-Perugini, V.; Montpellier, C.; Delgrange, D.; Wychowski, C.; Helle, F.; Pillez, A.; Drobecq, H.; Le Naour, F.; Charrin, S.; Levy, S.; et al. The CD81 partner EWI-2wint inhibits hepatitis C virus entry. PLoS One 2008, 3, e1866.
190. Stipp, C.S.; Kolesnikova, T.V.; Hemler, M.E. EWI-2 is a major CD9 and CD81 partner and member of a novel Ig protein subfamily. J. Biol. Chem. 2001, 276, 40545-40554.
191. Stipp, C.S.; Orlicky, D.; Hemler, M.E. FPRP, a major, highly stoichiometric, highly specific CD81-and CD9-associated protein. J. Biol. Chem. 2001, 276, 4853-4862.
192. Sala-Valdés, M.; Ursa, A.; Charrin, S.; Rubinstein, E.; Hemler, M.E.; Sánchez-Madrid, F.; Yáñez-Mó, M. EWI-2 and EWI-F link the tetraspanin web to the actin cytoskeleton through their direct association with ezrin-radixin-moesin proteins. J. Biol. Chem. 2006, 281, 19665-19675.
193. Stipp, C.S.; Kolesnikova, T.V.; Hemler, M.E. EWI-2 regulates alpha3beta1 integrin-dependent cell functions on laminin-5. J. Cell Biol. 2003, 163, 1167-1177.
194. Zhang, X.A.; Lane, W.S.; Charrin, S.; Rubinstein, E.; Liu, L. EWI2/PGRL associates with the metastasis suppressor KAI1/CD82 and inhibits the migration of prostate cancer cells. Canc. Res. 2003, 63, 2665-2674.
195. Charrin, S.; Yalaoui, S.; Bartosch, B.; Cocquerel, L.; Franetich, J.-F.; Boucheix, C.; Mazier, D.; Rubinstein, E.; Silvie, O. The Ig domain protein CD9P-1 down-regulates CD81 ability to support Plasmodium yoelii infection. J. Biol. Chem. 2009, 284, 31572-31578.
196. Burckhardt, C.J.; Greber, U.F. Virus movements on the plasma membrane support infection and transmission between cells. PLoS Pathog. 2009, 5, e1000621.
197. Harris, H.J.; Clerte, C.; Farquhar, M.J.; Goodall, M.; Hu, K.; Rassam, P.; Dosset, P.; Wilson, G.K.; Balfe, P.; Ijzendoorn, S.C.; et al. Hepatoma polarization limits CD81 and hepatitis C virus dynamics. Cell. Microbiol. 2012, 15, 430-445.
198. Espenel, C.; Margeat, E.; Dosset, P.; Arduise, C.; Le Grimellec, C.; Royer, C.A.; Boucheix, C.; Rubinstein, E.; Milhiet, P.-E. Single-molecule analysis of CD9 dynamics and partitioning reveals multiple modes of interaction in the tetraspanin web. J. Cell Biol. 2008, 182, 765-776.
199. Krementsov, D.N.; Rassam, P.; Margeat, E.; Roy, N.H.; Schneider-Schaulies, J.; Milhiet, P.-E.; Thali, M. HIV-1 Assembly Differentially Alters Dynamics and Partitioning of Tetraspanins and Raft Components. Traffic 2010, 11, 1401-1414.
200. Fletcher, N.F.; Sutaria, R.; Jo, J.; Barnes, A.; Blahova, M.; Meredith, L.W.; Cosset, F.-L.; Curbishley, S.M.; Adams, D.H.; Bertoletti, A.; et al. Activated macrophages promote hepatitis C virus entry in a tumor necrosis factor-dependent manner. Hepatology 2013, doi:10.1002/hep.26911.
201. Masciopinto, F.; Giovani, C.; Campagnoli, S.; Galli-Stampino, L.; Colombatto, P.; Brunetto, M.; Yen, T.S.B.; Houghton, M.; Pileri, P.; Abrignani, S. Association of hepatitis C virus envelope proteins with exosomes. Eur. J. Immunol. 2004, 34, 2834-2842.
202. Dreux, M.; Garaigorta, U.; Boyd, B.; Décembre, E.; Chung, J.; Whitten-Bauer, C.; Wieland, S.; Chisari, F.V. Short-range exosomal transfer of viral RNA from infected cells to plasmacytoid dendritic ells triggers innate immunity. Cell Host Microbe 2012, 12, 558-570.
203. Zhang, Y.-Y.; Zhang, B.-H.; Ishii, K.; Liang, T.J. Novel function of CD81 in controlling hepatitis C virus replication. J. Virol. 2010, 84, 3396-3407.
204. Ke, P.-Y.; Chen, S.S.-L. Active RNA replication of hepatitis C virus downregulates CD81 expression. PLoS One 2013, 8, e54866.
205. Tscherne, D.M.; Evans, M.J.; von Hahn, T.; Jones, C.T.; Stamataki, Z.; McKeating, J.A.; Lindenbach, B.D.; Rice, C.M. Superinfection exclusion in cells infected with hepatitis C virus. J. Virol. 2007, 81, 3693-3703.
206. Zignego, A.L.; Giannini, C.; Gragnani, L. HCV and Lymphoproliferation. Clin. Dev. Immunol. 2012, 2012, 1-8.
207. Agnello, V.; Chung, R.T.; Kaplan, L.M. A role for hepatitis C virus infection in type II cryoglobulinemia. N. Engl. J. Med. 1992, 327, 1490-1495.
208. Engels, E.A.; Chatterjee, N.; Cerhan, J.R.; Davis, S.; Cozen, W.; Severson, R.K.; Whitby, D.; Colt, J.S.; Hartge, P. Hepatitis C virus infection and non-hodgkin lymphoma: Results of the NCI-seer multi-center case-control study. Int. J. Canc. 2004, 111, 76-80.
209. Sansonno, D.; Carbone, A.; De Re, V.; Dammacco, F. Hepatitis C virus infection, cryoglobulinaemia, and beyond. Rheumatology (Oxford) 2007, 46, 572-578.
210. Cocquerel, L.; Kuo, C.-C.; Dubuisson, J.; Levy, S. CD81-dependent binding of hepatitis C virus E1E2 heterodimers. J. Virol. 2003, 77, 10677-10683.
211. Rosa, D.; Saletti, G.; De Gregorio, E.; Zorat, F.; Comar, C.; D'Oro, U.; Nuti, S.; Houghton, M.; Barnaba, V.; Pozzato, G.; et al. Activation of naïve B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders. Proc. Natl. Acad. Sci. USA 2005, 102, 18544-18549.
212. Machida, K.; Cheng, K.T. H.; Pavio, N.; Sung, V.M.H.; Lai, M.M. C. Hepatitis C Virus E2-CD81 interaction induces hypermutation of the immunoglobulin gene in B cells. J. Virol. 2005, 79, 8079-8089.
213. Chen, Z.; Zhu, Y.; Ren, Y.; Tong, Y.; Hua, X.; Zhu, F.; Huang, L.; Liu, Y.; Luo, Y.; Lu, W.; Zhao, P.; Qi, Z. Hepatitis C Virus protects human B lymphocytes from Fas-Mediated apoptosis via E2-CD81 engagement. PLoS One 2011, 6, e18933.
214. Ni, J.; Hembrador, E.; Di Bisceglie, A.M.; Jacobson, I.M.; Talal, A.H.; Butera, D.; Rice, C.M.; Chambers, T.J.; Dustin, L.B. Accumulation of B lymphocytes with a naive, resting phenotype in a subset of hepatitis C patients. J. Immunol. 2003, 170, 3429-3439.
215. Takahashi, S.; Doss, C.; Levy, S.; Levy, R. TAPA-1, the target of an antiproliferative antibody, is associated on the cell surface with the Leu-13 antigen. J. Immunol. 1990, 145, 2207-2213.
216. Raychoudhuri, A.; Shrivastava, S.; Steele, R.; Kim, H.; Ray, R.; Ray, R.B. ISG56 and IFITM1 Proteins Inhibit Hepatitis C Virus Replication. J. Virol. 2011, 85, 12881-12889.
217. Wilkins, C.; Woodward, J.; Lau, D.T. Y.; Barnes, A.; Joyce, M.; McFarlane, N.; McKeating, J.A.; Tyrrell, D.L.; Gale, M., Jr. IFITM1 is a tight junction protein that inhibits hepatitis C virus entry. Hepatology 2012, 57, 461-469.
218. Tseng, C.T.K.; Klimpel, G.R. Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. J. Exp. Med. 2002, 195, 43-50.
219. Crotta, S.; Stilla, A.; Wack, A.; D'Andrea, A.; Nuti, S.; D'Oro, U.; Mosca, M.; Filliponi, F.; Brunetto, R.M.; Bonino, F.; et al. Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J. Exp. Med. 2002, 195, 35-42.
220. Crotta, S.; Ronconi, V.; Ulivieri, C.; Baldari, C.T.; Valiante, N.M.; Valiente, N.M.; Abrignani, S.; Wack, A. Cytoskeleton rearrangement induced by tetraspanin engagement modulates the activation of T and NK cells. Eur. J. Immunol. 2006, 36, 919-929.
221. Corado, J.; Toro, F.; Rivera, H.; Bianco, N.E.; Deibis, L.; De Santis, J.B. Impairment of natural killer (NK) cytotoxic activity in hepatitis C virus (HCV) infection. Clin. Exp. Immunol. 1997, 109, 451-457.
222. Yoon, J.C.; Shiina, M.; Ahlenstiel, G.; Rehermann, B. Natural killer cell function is intact after direct exposure to infectious hepatitis C virions. Hepatology 2009, 49, 12-21.
223. Holder, K.A.; Stapleton, S.N.; Gallant, M.E.; Russell, R.S.; Grant, M.D. Hepatitis C Virus infected cells downregulate NKp30 and inhibit ex vivo NK cell functions. J. Immunol. 2013, 191, 3308-3318.
224. Farag, M.M.S.; Weigand, K.; Encke, J.; Momburg, F. Activation of natural killer cells by hepatitis C virus particles in vitro. Clin. Exp. Immunol. 2011, 165, 352-362.
225. Crotta, S.; Brazzoli, M.; Piccioli, D.; Valiante, N.M.; Wack, A. Hepatitis C virions subvert natural killer cell activation to generate a cytokine environment permissive for infection. J. Hepatol. 2010, 52, 183-190.
226. Zhang, S.; Saha, B.; Kodys, K.; Szabo, G. IFN- production by human natural killer cells in response to HCV-infected hepatoma cells is dependent on accessory cells. J. Hepatol. 2013, 59, 442-449.
227. Tseng, C. Characterization of liver T-cell receptor γδ+ T cells obtained from individuals chronically infected with hepatitis C virus (HCV): Evidence for these T cells playing a role in the liver pathology associated with HCV infections. Hepatology 2001, 33, 1312-1320.
228. Tseng, C.-T.K.; Miskovsky, E.; Klimpel, G.R. Crosslinking CD81 Results in Activation of TCRγδ T Cells. Cell. Immunol. 2001, 207, 19-27.
229. Wack, A.; Soldaini, E.; Tseng, C.-T.K.; Nuti, S.; Klimpel, G.R.; Abrignani, S. Binding of the hepatitis C virus envelope protein E2 to CD81 provides a co-stimulatory signal for human T cells. Eur. J. Immunol. 2001, 31, 166-175.
230. Soldaini, E.; Wack, A.; D'Oro, U.; Nuti, S.; Ulivieri, C.; Baldari, C.T.; Abrignani, S. T cell costimulation by the hepatitis C virus envelope protein E2 binding to CD81 is mediated by Lck. Eur. J. Immunol. 2003, 33, 455-464.
231. Averill, L.; Lee, W.M.; Karandikar, N.J. Differential dysfunction in dendritic cell subsets during chronic HCV infection. Clin. Immunol. 2007, 123, 40-49.
232. Szabo, G.; Dolganiuc, A. Subversion of plasmacytoid and myeloid dendritic cell functions in chronic HCV infection. Immunobiology 2005, 210, 237-247.
233. Lai, W.K.; Curbishley, S.M.; Goddard, S.; Alabraba, E.; Shaw, J.; Youster, J.; McKeating, J.; Adams, D.H. Hepatitis C is associated with perturbation of intrahepatic myeloid and plasmacytoid dendritic cell function. J. Hepatol. 2007, 47, 338-347.
234. Shiina, M.; Rehermann, B. Cell culture-produced hepatitis C virus impairs plasmacytoid dendritic cell function. Hepatology 2007, 47, 385-395.
235. Liang, H.; Russell, R.S.; Yonkers, N.L.; McDonald, D.; Rodriguez, B.; Harding, C.V.; Anthony, D.D. Differential effects of hepatitis C virus JFH1 on human myeloid and plasmacytoid dendritic cells. J. Virol. 2009, 83, 5693-5707.
236. Longman, R.S.; Talal, A.H.; Jacobson, I.M.; Rice, C.M.; Albert, M.L. Normal functional capacity in circulating myeloid and plasmacytoid dendritic cells in patients with chronic hepatitis C. J. Infect. Dis. 2005, 192, 497-503.
237. Piccioli, D.; Tavarini, S.; Nuti, S.; Colombatto, P.; Brunetto, M.; Bonino, F.; Ciccorossi, P.; Zorat, F.; Pozzato, G.; Comar, C.; et al. Comparable functions of plasmacytoid and monocyte-derived dendritic cells in chronic hepatitis C patients and healthy donors. J. Hepatol. 2005, 42, 61-67.
238. Albert, M.L.; Decalf, J.; Pol, S. Plasmacytoid dendritic cells move down on the list of suspects: In search of the immune pathogenesis of chronic hepatitis C. J. Hepatol. 2008, 49, 1069-1078.
239. Nattermann, J.; Zimmermann, H.; Iwan, A.; von Lilienfeld-Toal, M.; Leifeld, L.; Nischalke, H.D.; Langhans, B.; Sauerbruch, T.; Spengler, U. Hepatitis C virus E2 and CD81 interaction may be associated with altered trafficking of dendritic cells in chronic hepatitis C. Hepatology 2006, 44, 945-954.
240. Zhang, S.; Kodys, K.; Babcock, G.J.; Szabo, G. CD81/CD9 tetraspanins aid plasmacytoid dendritic cells in recognition of hepatitis C virus-infected cells and induction of interferon-alpha. Hepatology 2013, 58, 940-949.
241. Takahashi, K.; Asabe, S.; Wieland, S.; Garaigorta, U.; Gastaminza, P.; Isogawa, M.; Chisari, F.V. Plasmacytoid dendritic cells sense hepatitis C virus-infected cells, produce interferon, and inhibit infection. Proc. Natl. Acad. Sci. USA 2010, 107, 7431-7436.
242. Tu, Z.; Zhang, P.; Li, H.; Niu, J.; Jin, X.; Su, L. Cellular Immunology. Cell. Immunol. 2013, 284, 98-103.
243. Zona, L.; Tawar, R.G.; Zeisel, M.B.; Xiao, F.; Schuster, C.; Lupberger, J.; Baumert, T.F. Tetraspanin-co-receptor associations-Impact for hepatitis C virus entry and antiviral therapies. Viruses 2014, submitted for publication.